Patents by Inventor Kenneth Phelps

Kenneth Phelps has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9314524
    Abstract: The invention relates to topical formulations of flucytosine which demonstrate a clear advantage over currently available therapeutic regimens for the treatment and maintenance of fungal infections, particularly vulvovaginal candidiasis. The invention provides compositions which solve the long-standing need for antimicrobial agents which treat effectively resistant strains of Candida spp., especially C. albicans, C. glabrata, and C. tropicalis, and which pose limited risk of side effects, adverse reactions, or the development of resistant pathogens. The invention provides novel topical formulations of flucytosine designed to allow the active drug to act at the local application area, but which inhibit or moderate transdermal or transmucosal absorption of the drug, thus limiting systemic exposure.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: April 19, 2016
    Assignee: CALLA THERAPEUTICS LLC
    Inventors: Jaber Qasem, Raymond H. Farmen, Kenneth Phelps
  • Publication number: 20090170876
    Abstract: The invention relates to topical formulations of flucytosine which demonstrate a clear advantage over currently available therapeutic regimens for the treatment and maintenance of fungal infections, particularly vulvovaginal candidiasis. The invention provides compositions which solve the long-standing need for antimicrobial agents which treat effectively resistant strains of Candida spp., especially C. albicans, C. glabrata, and C. tropicalis, and which pose limited risk of side effects, adverse reactions, or the development of resistant pathogens. The invention provides novel topical formulations of flucytosine designed to allow the active drug to act at the local application area, but which inhibit or moderate transdermal or transmucosal absorption of the drug, thus limiting systemic exposure.
    Type: Application
    Filed: December 23, 2008
    Publication date: July 2, 2009
    Applicant: CAMARGO PHARMACEUTICAL SERVICES, LLC
    Inventors: Jaber Qasem, Raymond H. Farmen, Kenneth Phelps